Managing Weight Loss Plateau with GLP-1 Therapy

Primary Recommendation

The American College of Cardiology recommends switching to tirzepatide, a dual GIP/GLP-1 agonist, for patients who have plateaued on GLP-1 therapy, as it demonstrates superior weight loss (20.9% vs 14.9% with semaglutide) 1, 2
Transition to tirzepatide 15mg weekly as the first-line intervention for patients on semaglutide or liraglutide who have plateaued, leveraging dual receptor activation for enhanced metabolic benefits 2

For patients without cardiovascular disease, the Endocrine Society suggests adding phentermine/topiramate ER to the existing GLP-1 regimen for additional appetite suppression, providing 6.6% weight loss at 1 year 3, 4
The American Heart Association recommends adding naltrexone/bupropion ER for patients describing food cravings or addictive eating behaviors, providing 4.8% weight loss at 56 weeks 3, 4
For patients who cannot tolerate stimulants, the American Gastroenterological Association suggests adding orlistat 120mg three times daily with meals, providing modest additional 3.1% weight loss at 1 year 3

Ensure patient is on maximum tolerated dose of GLP-1 therapy (semaglutide 2.4mg weekly or liraglutide 3.0mg daily) before adding combination therapy, as recommended by the American Diabetes Association 1, 2
Define "plateau" as <5% total weight loss after 3 months at maximum dose, and consider switching or adding therapy, according to the Obesity Society 1, 3
Address potential causes of plateau, including concomitant medications, hypothyroidism, and GLP-1 resistance mechanisms, as suggested by the Endocrine Society 1, 2

Assess patients monthly for the first 3 months after adding combination therapy, then every 3 months thereafter, monitoring for additive gastrointestinal effects and cardiovascular effects, as recommended by the American Heart Association 2, 3
Discontinue added medication if <5% additional weight loss at 12 weeks, according to the American College of Cardiology 3
Avoid combining two GLP-1 receptor agonists simultaneously, and do not combine GLP-1 agonists with DPP-4 inhibitors, as contraindicated by the American Diabetes Association 2